OncoMatch/Clinical Trials/NCT07125547
Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer
Is NCT07125547 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including PD-1 inhibitior and Nab-paclitaxel for ureteral cancer.
Treatment: PD-1 inhibitior · Nab-paclitaxel — This study is designed as an open-label, single-arm, single-center, phase II clinical trial, aiming to evaluate the efficacy and safety of neoadjuvant Tislelizumab combined with Nab-Paclitaxel followed by distal ureterectomy for patients with non-metastatic ureteral cancer (UTC). Patients enrolled will receive 2-3 cycles of Tislelizumab in combination with Nab-Paclitaxel every 3 weeks and then undergo distal ureterectomy (DU). The assessment of efficacy is based on the histology of specimen from DU, and treatment-related adverse events (TRAEs) will be recorded and evaluated according to CTCAE 5.0.
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: PD-1/PD-L1/CTLA-4 immune checkpoint inhibitor
Previous treatment with PD-1/PD-L1/CTLA-4 immune checkpoint inhibitors or other immunotherapies
Lab requirements
Blood counts
absolute neutrophil count ≥1.5×10^9/l, platelet count ≥80×10^9/l, hemoglobin ≥6.0 g/dl (can be maintained through symptomatic treatment)
Kidney function
baseline ect renography indicates a total renal glomerular filtration rate (gfr) ≥15 ml/min, with the affected-side gfr >10 ml/min, excluding the presence of a non-functional kidney (low-level decreasing curve on dynamic renal ect imaging) on the affected side
Liver function
total bilirubin ≤1.5 times the upper limit of normal, alanine transaminase and aspartate transaminase ≤2.5 times the upper limit of normal
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify